Nanoparticles, Genome Therapy & Antibodies - The Zhou Research Lab at Yale School of Medicine

Why It Matters

By creating delivery platforms that breach the brain’s defenses, the lab could unlock effective therapies for cancers, strokes, and neurodegenerative diseases, dramatically expanding the clinical pipeline for hard‑to‑treat neurological conditions.

Key Takeaways

• Lab integrates engineering and biology for brain drug delivery.
• Nanoparticle platform targets brain cancer, stroke, and barrier crossing.
• Step engineering delivers gelatinous gene therapy for neuro-genetic diseases.
• Antibody program aims cell-penetrating antibodies for Parkinson’s, Huntington’s.
• Clinical translation planned within two years via physician collaborations.

Summary

The Zhou Research Lab at Yale School of Medicine is a biomedical‑engineering group that builds platform technologies for delivering therapeutics to the brain. Its work spans three distinct avenues: engineered nanoparticles for crossing the blood‑brain barrier, a novel “step‑engineering” approach that delivers gelatinous gene‑therapy vectors for neuro‑genetic disorders, and a new class of cell‑penetrating antibodies aimed at diseases such as Parkinson’s and Huntington’s.

The lab emphasizes technology over biology, leveraging established biological methods while innovating on delivery mechanisms. Nanoparticles are being optimized for brain‑cancer and stroke applications, step‑engineering is positioned as the only global effort targeting gelatinous gene therapy, and antibody engineering seeks intracellular access to treat neurodegenerative conditions. All three platforms are slated for clinical translation, with nanoparticle trials expected within two years and antibody candidates moving toward near‑term clinical use.

Collaboration is central to the lab’s strategy. Partnerships with physicians—such as Dr. *** for oncology, Professor James Hansen for antibody work, and Kevin *** for stroke research—provide the clinical insight needed to move discoveries from bench to bedside. The team explicitly avoids reinventing biological assays, focusing instead on engineering breakthroughs that can be rapidly deployed in clinical settings.

If successful, these technologies could reshape treatment paradigms for a range of neurological diseases, offering targeted delivery that overcomes the brain’s protective barriers. The lab’s translational focus promises to accelerate the pipeline from academic research to FDA‑approved therapies, potentially delivering new options for patients with limited current treatments.

Original Description

For more information on Jiangbing Zhou or #YaleSchoolOfMedicine, visit: https://medicine.yale.edu/profile/jiangbing-zhou and https://medicine.yale.edu/lab/zhou.

The Zhou Research Lab focuses on developing translational nanomedicine, gene therapy, and stem cell therapy for treatment of neurological disorders through a unique combination of material science, biology, and engineering.

0:00 What are they studying?

0:29 How are they studying it?

1:36 Where might this research lead?